市場調査レポート

商品コード

1737058

アルツハイマー病市場：治療タイプ別、対症的適応別、主要地域別

Alzheimer's Disease Market Distribution by Type of Treatment, Symptomatic Indications, and Key Geographical Regions

出版日: 2025年05月26日
発行: Roots Analysis
ページ情報: 英文 150 Pages
納期: 即日から翌営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,799 695,855円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (One-Location Site License)

USD 6,999 1,014,855円

レポートPDFを同一所在地における特定事業ユニットに属する全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Department License)

USD 10,599 1,536,855円

レポートPDFを部署単位で12名様までご利用いただけるライセンスです。同一部署内であれば、地理的に同じ地点に存在する必要はありません。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 17,999 2,609,855円

レポートPDFを同社の国内外拠点における全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=145.00円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のアルツハイマー病の市場規模は、2030年までの予測期間中に9%のCAGRで拡大し、現在の124億米ドルから2030年までに191億米ドルに成長すると予測されています。

市場セグメンテーションでは、市場規模および市場機会を以下のパラメータで区分しています：

治療タイプ別

対症療法
疾患修飾

対症的適応別

認知症
不眠症
その他の生理的症状

主要地域別

北米
欧州
アジア太平洋
その他の地域

アルツハイマー病市場：成長と動向

アルツハイマー病は、脳細胞の死によって特徴づけられる進行性の神経疾患であり、最終的には記憶喪失、認知機能障害、認知症を引き起こします。認知症の60～70％を占めるアルツハイマー病は、米国における死亡原因の第6位であることが知られています。現在、全年齢層で約700万人のアメリカ人がアルツハイマー病を患っており、この数は2050年までに約1,300万人に達すると予測されています。アルツハイマー病に関連する主な症状には、見当識障害、性格／行動の変化、出来事／時間／場所の混乱、重度の記憶喪失などがあります。また、会話、嚥下、歩行が困難になることも知られています。特に、病気が進行するにつれて、前述の症状はより顕著になり、脳細胞の死を助長します。その結果、革新的なアルツハイマー病治療の進歩は、この分野に携わる利害関係者に有利な機会を提供します。

アルツハイマー病に関連する社会経済的負担を考慮すると、製薬企業は信頼性の高い診断テストと、この病気の進行を遅らせることができる効果的なアルツハイマー病治療の選択肢を探してきました。現在、世界のさまざまな地域に拠点を置く160以上の企業が、アルツハイマー病治療のための薬物療法を開発するためのイニシアチブをとっています。

アルツハイマー病市場：主要インサイト

当レポートでは、アルツハイマー病市場の現状を掘り下げ、業界内の潜在的な成長機会を特定しています。当レポートの主な調査結果は以下の通り：

現在、世界の様々な地域を拠点とする160以上の企業がアルツハイマー病の薬物療法開発に取り組んでおり、市場は老舗企業と小規模企業が混在しているのが特徴です。
パイプラインには、様々な開発段階において単剤または他の治療薬との併用で評価されている240以上の薬物療法があり、これらのほとんどは経口投与用に設計されています。

アルツハイマー病の診断、治療、管理に関連する科学文献の出版は著しく増加しています。
アルツハイマー病に関連する知的財産もまた増加しており、薬剤分子に関連する数多くの特許が様々な団体別出願され、また様々な団体に付与されています。
ここ数年、この領域で進行中の研究開発活動を支援するために、いくつかの組織が財政的支援を提供しています。
過去10年間で、アルツハイマー病の薬物療法を評価するために、様々な地域にわたっていくつかの臨床試験が登録され、これらの臨床試験の多くはすでに完了しています。
この臨床症状を治療するために開発されている薬剤候補に関連する利益と機会により、最近の動向では164の事例で40億米ドル以上を投資している投資家もいます。
アルツハイマー病治療薬の全体的な市場機会は、さまざまなタイプの治療、症状の適応、主要な地域にわたって分布していると思われます。

アルツハイマー病市場：主要セグメント

治療タイプ別では、市場は対症療法型と疾患修飾型に区分されます。現在のところ、疾患修飾型が世界のアルツハイマー病市場で最大のシェアを占めています。さらに、対症療法分野は他の分野と比較して成長ペースが速いと思われます。

対症的適応別では、認知症、不眠症、その他の精神症状に分類されます。認知症状を治療するために開発される治療薬の数が増加していることから、現在、認知症分野が世界のアルツハイマー病市場で最も高い割合を占めています。さらに、不眠症のアルツハイマー病市場は、比較的高いCAGRで成長する可能性が高いことは注目に値します。

主要地域別に見ると、市場は北米、欧州、アジア太平洋地域、その他の地域に区分されます。現在、北米はアルツハイマー病市場を独占しており、同地域の良好な規制環境のために最大の収益シェアを占めています。実際、北米の規制機関は最近いくつかの新しいアルツハイマー病治療薬を承認しており、患者に革新的な治療法を提供し、市場の成長を後押ししています。さらに、欧州の市場は今後数年間、より高いCAGRで成長する可能性が高いです。

当レポートでは、世界のアルツハイマー病市場について調査し、市場の概要とともに、治療タイプ別、対症的適応別、主要地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

予測調査手法と主要な前提条件
世界のアルツハイマー病市場（2035年まで）
2035年までの世界のアルツハイマー病市場：治療タイプ別分布
2035年までの世界のアルツハイマー病市場：対症的適応別分布
2035年までの世界のアルツハイマー病市場：地域別分布
- 北米におけるアルツハイマー病市場（2035年まで）
- 欧州におけるアルツハイマー病市場（2035年まで）
- アジア太平洋のアルツハイマー病市場（2035年まで）

第15章結論

第16章エグゼクティブ洞察

第17章付録1：表形式データ

第18章付録2：企業・団体一覧

図表

List of Tables

Table 4.1 Alzheimer's Disease: Marketed and Clinical Development Pipeline
Table 4.2 Alzheimer's Disease Therapies: List of Developers
Table 6.1 Alzheimer's Disease Therapies: List of Terminated Drugs
Table 7.1 Alzheimer's Disease: List of Publications
Table 8.1 Alzheimer's Disease: List of Partnerships and Collaborations
Table 9.1 Alzheimer's Disease: List of Funding and Investments
Table 10.1 Alzheimer's Disease: List of Academic Grants
Table 11.1 Alzheimer's Disease: List of Clinical Trials
Table 12.1 Alzheimer's Disease: List of Patents
Table 17.1. Marketed and Clinical-Stage Drugs: Distribution by Phase of Development
Table 17.2. Marketed and Clinical-Stage Drugs: Distribution by Type of Molecule
Table 17.3. Marketed and Clinical-Stage Drugs: Distribution by Target Disease Stage
Table 17.4. Marketed and Clinical-Stage Drugs: Distribution by Type of Treatment
Table 17.5. Marketed and Clinical-Stage Drugs: Distribution by Mechanism of Action
Table 17.6. Marketed and Clinical-Stage Drugs: Distribution by Route of Administration
Table 17.7. Marketed and Clinical-Stage Drugs: Distribution by Dosing Frequency
Table 17.8. Marketed and Clinical-Stage Drugs: Distribution by Type of Therapy
Table 17.9. Marketed and Clinical-Stage Drugs: Distribution by Path to Clinic
Table 17.10. Grid Analysis: Distribution by Phase of Development, Path to Clinic and Type of Therapy
Table 17.11. Alzheimer's Disease Therapies: List of Developers
Table 17.12. Alzheimer's Disease Therapy Developers: Distribution by Year of Establishment
Table 17.13. Alzheimer's Disease Therapy Developers: Distribution by Company Size and Geographical Location of Headquarters
Table 17.14. Leading Players: Distribution by Number of Therapies
Table 17.15. Alzheimer's Disease Therapy Developers: Distribution by Geography
Table 17.16. AbbVie: Financial Information
Table 17.17. AC Immune: Financial Information
Table 17.18. Biogen: Financial Information
Table 17.19. Eisai: Financial Information
Table 17.20. Eli Lilly and Company: Financial Information
Table 17.21. GlaxoSmithKline: Financial Information
Table 17.22. Grifols: Financial Information
Table 17.23. Janssen Pharmaceutical: Financial Information
Table 17.24. Neurim Pharmaceuticals: Financial Information
Table 17.25. Novartis: Financial Information
Table 17.26. Novo Nordisk: Financial Information
Table 17.27. Roche: Financial Information
Table 17.28. Takeda Pharmaceutical: Financial Information
Table 17.29. Terminated Drugs: Distribution by Year of Discontinuation
Table 17.30. Terminated Drugs: Distribution by Phase of Discontinuation
Table 17.31. Terminated Drugs: Distribution by Mechanism of Action
Table 17.32. Terminated Drugs: Distribution by Type of Indication
Table 17.33. Terminated Drugs: Distribution by Reason for Termination
Table 17.34. Terminated Drugs: Distribution by Affiliated Stakeholders
Table 17.35. Terminated Drugs: Distribution by Study Start Year and Year of Termination of Clinical Trials
Table 17.36. Terminated Drugs: Distribution by Location of Trials
Table 17.37. Publication Analysis: Distribution by Year of Publication
Table 17.38. Publication Analysis: Distribution by Key Focus Area
Table 17.39. Publication Analysis: Word Cloud of Study Titles
Table 17.40. Top Journals: Distribution by Number of Publications
Table 17.41. Top Authors: Distribution by Number of Publications
Table 17.42. Partnerships and Collaborations: Distribution by Year of Partnership
Table 17.43. Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.44. Partnerships and Collaborations: Distribution by Type of Partnership and Focus Area of Partnership
Table 17.45. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Molecule
Table 17.46. Most Active Players: Distribution by Number of Partnerships
Table 17.47. Partnerships and Collaborations: Regional Distribution
Table 17.48. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 17.49. Funding and Investment Analysis: Distribution by Year of Investment
Table 17.50. Funding and Investment Analysis: Distribution by Amount Invested
Table 17.51. Funding and Investment Analysis: Distribution by Type of Funding
Table 17.52. Funding and Investment Analysis: Distribution by Amount Invested Across Different Types of Molecules
Table 17.53. Funding and Investment Analysis: Distribution by Amount Invested Across Different Types of Mechanism of Action
Table 17.54. Funding and Investment Analysis: Regional Distribution by Amount Invested
Table 17.55. Most Active Players: Distribution by Number of Funding Instances
Table 17.56. Most Active Investors: Distribution by Amount Funded
Table 17.57. Grant Analysis: Distribution by Year of Grant Award
Table 17.58. Grant Analysis: Distribution by Grant Amount Awarded
Table 17.59. Grant Analysis: Distribution by Administering Institute Center
Table 17.60. Grant Analysis: Distribution by Support Period
Table 17.61. Grant Analysis: Distribution by Administering Institute Center and Support Year
Table 17.62. Grant Analysis: Distribution by Type of Grant Application
Table 17.63. Grant Analysis: Distribution by Grant Activity Code
Table 17.64. Grant Analysis: Word Cloud of Study Titles
Table 17.65. Grant Analysis: Distribution by Purpose of Grant Award
Table 17.66. Grant Analysis: Distribution by Type of Recipient Organization
Table 17.67. Popular NIH Departments: Distribution by Number of Grants
Table 17.68. Prominent Program Officers: Distribution by Number of Grants
Table 17.69. Clinical Trial Analysis: Distribution by Trial Status
Table 17.70. Clinical Trial Analysis: Distribution by Trial Registration Year
Table 17.71. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 17.72. Clinical Trial Analysis: Distribution by Type of Study Design
Table 17.73. Clinical Trial Analysis: Distribution by Registration Year and Type of Study
Table 17.74. Clinical Trial Analysis: Distribution by Patient Enrollment
Table 17.75. Clinical Trial Analysis: Year-wise Trend of Completed and Recruiting Trials
Table 17.76. Clinical Trial Analysis: Distribution by Age Category
Table 17.77. Clinical Trial Analysis: Word Cloud of Study Titles
Table 17.78. Most Active Industry Players: Distribution by Number of Registered Trials
Table 17.79. Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 17.80. Clinical Trial Analysis: Distribution by Trial Location
Table 17.81. Clinical Trial Analysis: Distribution by Trial Status and Geography
Table 17.82. Patent Analysis: Distribution by Patent Application Year
Table 17.83. Patent Analysis: Distribution by Geography
Table 17.84. Patent Analysis: Distribution by CPC Symbols
Table 17.85. Word Cloud: Emerging Focus Areas
Table 17.86. Patent Analysis: Distribution by Type of Applicant
Table 17.87. Leading Players: Distribution by Number of Patents
Table 17.88. Leading Players: Distribution by Number of International Patents
Table 17.89. Patent Analysis: Patent Valuation Analysis
Table 17.90. Non-Pharmacological Interventions for Alzheimer's Disease
Table 17.91. Cognition / Emotion-Oriented Interventions
Table 17.92. Reminiscence Therapy
Table 17.93. Simulated Presence Therapy
Table 17.94. Sensory Stimulation-based Interventions
Table 17.95. Virtual Reality
Table 17.96. Music Therapy
Table 17.97. Light Therapy
Table 17.98. Aromatherapy
Table 17.99. Reflexology
Table 17.100. Other Psycho-social Interventions
Table 17.12. Animal-Assisted Therapy
Table 17.1. Global Alzheimer's Disease Market, Till 2035 (USD Million)
Table 17.2. Global Alzheimer's Disease Market, Till 2035: Distribution by Type of Treatment (USD Million)
Table 17.3. Global Alzheimer's Disease Market, Till 2035: Distribution by Type of Target Disease Indication (USD Million)
Table 17.4. Global Alzheimer's Disease Market, Till 2035: Distribution by Geography (USD Million)
Table 17.5. Alzheimer's Disease Market in North America, Till 2035 (USD Million)
Table 17.6. Alzheimer's Disease Market in North America, Till 2035: Distribution by Type of Treatment (USD Million)
Table 17.7. Alzheimer's Disease Market in North America, Till 2035: Distribution by Symptomatic Treatment (USD Million)
Table 17.8. Alzheimer's Disease Market in North America, Till 2035: Share of Dementia in Symptomatic Treatment Market (USD Million)
Table 17.9. Alzheimer's Disease Market in North America, Till 2035: Share of Insomnia in Symptomatic Treatment Market (USD Million)
Table 17.10. Alzheimer's Disease Market in North America, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market (USD Million)
Table 17.11. Alzheimer's Disease Market in North America, Till 2035: Distribution by Disease Modifying Treatment (USD Million)
Table 17.12. Alzheimer's Disease Market in Europe, Till 2035 (USD Million)
Table 17.13. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Type of Treatment (USD Million)
Table 17.17. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Symptomatic Treatment (USD Million)
Table 17.15. Alzheimer's Disease Market in Europe, Till 2035: Share of Dementia in Symptomatic Treatment Market (USD Million)
Table 17.16. Alzheimer's Disease Market in Europe, Till 2035: Share of Insomnia in Symptomatic Treatment Market (USD Million)
Table 17.17. Alzheimer's Disease Market in Europe, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market (USD Million)
Table 17.18. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Disease Modifying Treatment (USD Million)
Table 17.19. Alzheimer's Disease Market in Asia-Pacific, Till 2035(USD Million)
Table 17.20. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Type of Treatment (USD Million)
Table 17.21. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Symptomatic Treatment (USD Million)
Table 17.22. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Dementia in Symptomatic Treatment (USD Million)
Table 17.23. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Insomnia in Symptomatic Treatment (USD Million)
Table 17.24. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment (USD Million)
Table 17.25. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Disease Modifying Treatment (USD Million)

List of Figures

Figure 3.1. Overview of Alzheimer's Disease
Figure 3.2. Alzheimer's Disease: Signs and Symptoms
Figure 3.3. Causes of Alzheimer's Disease
Figure 3.4. Stages of Alzheimer's Disease
Figure 3.5. Alzheimer's Disease Management: Programs Undertaken by The National Institutes of Health
Figure 3.6. Alzheimer's Disease Management
Figure 3.7. Digital Biomarkers in Alzheimer's Disease
Figure 3.8. Potential of Digital Biomarkers in Alzheimer's Disease
Figure 3.9. Sensors or Digital Senses in Wearable / Mobile Devices for Alzheimer's Disease
Figure 4.1. Marketed and Clinical-Stage Drugs: Distribution by Phase of Development
Figure 4.2. Marketed and Clinical-Stage Drugs: Distribution by Type of Molecule
Figure 4.3. Marketed and Clinical-Stage Drugs: Distribution by Target Disease Stage
Figure 4.4. Marketed and Clinical-Stage Drugs: Distribution by Type of Treatment
Figure 4.5. Marketed and Clinical-Stage Drugs: Distribution by Mechanism of Action
Figure 4.6. Marketed and Clinical-Stage Drugs: Distribution by Route of Administration
Figure 4.7. Marketed and Clinical-Stage Drugs: Distribution by Dosing Frequency
Figure 4.8. Marketed and Clinical-Stage Drugs: Distribution by Type of Therapy
Figure 4.9. Marketed and Clinical-Stage Drugs: Distribution by Path to Clinic
Figure 4.10. Grid Analysis: Distribution by Phase of Development, Path to Clinic and Type of Therapy
Figure 4.11. Alzheimer's Disease Therapies: List of Developers
Figure 4.12. Alzheimer's Disease Therapy Developers: Distribution by Year of Establishment
Figure 4.13. Alzheimer's Disease Therapy Developers: Distribution by Company Size and Geographical Location of Headquarters
Figure 4.14. Leading Players: Distribution by Number of Therapies
Figure 4.15. Alzheimer's Disease Therapy Developers: Distribution by Geography
Figure 5.1. AbbVie: Financial Information
Figure 5.2. AC Immune: Financial Information
Figure 5.3. Biogen: Financial Information
Figure 5.4. Eisai: Financial Information
Figure 5.5. Eli Lilly and Company: Financial Information
Figure 5.6. GlaxoSmithKline: Financial Information
Figure 5.7. Grifols: Financial Information
Figure 5.8. Janssen Pharmaceutical: Financial Information
Figure 5.9. Neurim Pharmaceuticals: Financial Information
Figure 5.10. Novartis: Financial Information
Figure 5.11. Novo Nordisk: Financial Information
Figure 5.12. Roche: Financial Information
Figure 5.13. Takeda Pharmaceutical: Financial Information
Figure 6.1. Terminated Drugs: Distribution by Year of Discontinuation
Figure 6.2. Terminated Drugs: Distribution by Phase of Discontinuation
Figure 6.3. Terminated Drugs: Distribution by Mechanism of Action
Figure 6.4. Terminated Drugs: Distribution by Type of Indication
Figure 6.5. Terminated Drugs: Distribution by Reason for Termination
Figure 6.6. Terminated Drugs: Distribution by Affiliated Stakeholders
Figure 6.7. Terminated Drugs: Distribution by Study Start Year and Year of Termination of Clinical Trials
Figure 6.8. Terminated Drugs: Distribution by Location of Trials
Figure 7.1. Publication Analysis: Distribution by Year of Publication
Figure 7.2. Publication Analysis: Distribution by Key Focus Area
Figure 7.3. Publication Analysis: Word Cloud of Study Titles
Figure 7.4. Top Journals: Distribution by Number of Publications
Figure 7.5. Top Authors: Distribution by Number of Publications
Figure 8.1. Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3. Partnerships and Collaborations: Distribution by Type of Partnership and Focus Area of Partnership
Figure 8.4. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Molecule
Figure 8.5. Most Active Players: Distribution by Number of Partnerships
Figure 8.6. Partnerships and Collaborations: Regional Distribution
Figure 8.7. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1. Funding and Investment Analysis: Distribution by Year of Investment
Figure 9.2. Funding and Investment Analysis: Distribution by Amount Invested
Figure 9.3. Funding and Investment Analysis: Distribution by Type of Funding
Figure 9.4. Funding and Investment Analysis: Distribution by Amount Invested Across Different Types of Molecules
Figure 9.5. Funding and Investment Analysis: Distribution by Amount Invested Across Different Types of Mechanism of Action
Figure 9.6. Funding and Investment Analysis: Regional Distribution by Amount Invested
Figure 9.7. Most Active Players: Distribution by Number of Funding Instances
Figure 9.8. Most Active Investors: Distribution by Amount Funded
Figure 10.1. Grant Analysis: Distribution by Year of Grant Award
Figure 10.2. Grant Analysis: Distribution by Grant Amount Awarded
Figure 10.3. Grant Analysis: Distribution by Administering Institute Center
Figure 10.4. Grant Analysis: Distribution by Support Period
Figure 10.5. Grant Analysis: Distribution by Administering Institute Center and Support Year
Figure 10.6. Grant Analysis: Distribution by Type of Grant Application
Figure 10.7. Grant Analysis: Distribution by Grant Activity Code
Figure 10.8. Grant Analysis: Word Cloud of Study Titles
Figure 10.9. Grant Analysis: Distribution by Purpose of Grant Award
Figure 10.10. Grant Analysis: Distribution by Type of Recipient Organization
Figure 10.11. Popular NIH Departments: Distribution by Number of Grants
Figure 10.12. Prominent Program Officers: Distribution by Number of Grants
Figure 11.1. Clinical Trial Analysis: Distribution by Trial Status
Figure 11.2. Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 11.3. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 11.4. Clinical Trial Analysis: Distribution by Type of Study Design
Figure 11.5. Clinical Trial Analysis: Distribution by Registration Year and Type of Study
Figure 11.6. Clinical Trial Analysis: Distribution by Patient Enrollment
Figure 11.7. Clinical Trial Analysis: Year-wise Trend of Completed and Recruiting Trials
Figure 11.8. Clinical Trial Analysis: Distribution by Age Category
Figure 11.9. Clinical Trial Analysis: Word Cloud of Study Titles
Figure 11.10. Most Active Industry Players: Distribution by Number of Registered Trials
Figure 11.11. Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 11.12. Clinical Trial Analysis: Distribution by Trial Location
Figure 11.13. Clinical Trial Analysis: Distribution by Trial Status and Geography
Figure 12.1. Patent Analysis: Distribution by Patent Application Year
Figure 12.2. Patent Analysis: Distribution by Geography
Figure 12.3. Patent Analysis: Distribution by CPC Symbols
Figure 12.4. Word Cloud: Emerging Focus Areas
Figure 12.5. Patent Analysis: Distribution by Type of Applicant
Figure 12.6. Leading Players: Distribution by Number of Patents
Figure 12.7 Leading Players: Distribution by Number of International Patents
Figure 12.8. Patent Analysis: Patent Valuation Analysis
Figure 13.1. Non-Pharmacological Interventions for Alzheimer's Disease
Figure 13.2. Cognition / Emotion-Oriented Interventions
Figure 13.3. Reminiscence Therapy
Figure 13.4. Simulated Presence Therapy
Figure 13.5. Sensory Stimulation-based Interventions
Figure 13.6. Virtual Reality
Figure 13.7. Music Therapy
Figure 13.8. Light Therapy
Figure 13.9. Aromatherapy
Figure 13.10. Reflexology
Figure 13.11. Other Psycho-social Interventions
Figure 13.12. Animal-Assisted Therapy
Figure 14.1. Global Alzheimer's Disease Market, Till 2035 (USD Million)
Figure 14.2. Global Alzheimer's Disease Market, Till 2035: Distribution by Type of Treatment (USD Million)
Figure 14.3. Global Alzheimer's Disease Market, Till 2035: Distribution by Type of Target Disease Indication (USD Million)
Figure 14.4. Global Alzheimer's Disease Market, Till 2035: Distribution by Geography (USD Million)
Figure 14.5. Alzheimer's Disease Market in North America, Till 2035 (USD Million)
Figure 14.6. Alzheimer's Disease Market in North America, Till 2035: Distribution by Type of Treatment (USD Million)
Figure 14.7. Alzheimer's Disease Market in North America, Till 2035: Distribution by Symptomatic Treatment (USD Million)
Figure 14.8. Alzheimer's Disease Market in North America, Till 2035: Share of Dementia in Symptomatic Treatment Market (USD Million)
Figure 14.9. Alzheimer's Disease Market in North America, Till 2035: Share of Insomnia in Symptomatic Treatment Market (USD Million)
Figure 14.10. Alzheimer's Disease Market in North America, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market (USD Million)
Figure 14.11. Alzheimer's Disease Market in North America, Till 2035: Distribution by Disease Modifying Treatment (USD Million)
Figure 14.12. Alzheimer's Disease Market in Europe, Till 2035 (USD Million)
Figure 14.13. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Type of Treatment (USD Million)
Figure 14.14. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Symptomatic Treatment (USD Million)
Figure 14.15. Alzheimer's Disease Market in Europe, Till 2035: Share of Dementia in Symptomatic Treatment Market (USD Million)
Figure 14.16. Alzheimer's Disease Market in Europe, Till 2035: Share of Insomnia in Symptomatic Treatment Market (USD Million)
Figure 14.17. Alzheimer's Disease Market in Europe, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market (USD Million)
Figure 14.18. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Disease Modifying Treatment (USD Million)
Figure 14.19. Alzheimer's Disease Market in Asia-Pacific, Till 2035(USD Million)
Figure 14.20. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Type of Treatment (USD Million)
Figure 14.21. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Symptomatic Treatment (USD Million)
Figure 14.22. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Dementia in Symptomatic Treatment (USD Million)
Figure 14.23. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Insomnia in Symptomatic Treatment (USD Million)
Figure 14.24. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment (USD Million)
Figure 14.25. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Disease Modifying Treatment (USD Million)

Product Code: RA100297

ALZHEIMER'S DISEASE MARKET: OVERVIEW

As per Roots Analysis, the global Alzheimer's disease market is estimated to grow from USD 12.4 billion in the current year to USD 19.1 billion by 2030, at a CAGR of 9% during the forecast period, till 2030.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Treatment

Symptomatic
Disease Modifying

Symptomatic Indications

Dementia
Insomnia
Other Physiological Symptoms

Key Geographical Regions

North America
Europe
Asia-Pacific
Rest of the World

ALZHEIMER'S DISEASE MARKET: GROWTH AND TRENDS

Alzheimer's disease is a progressive neurological disorder characterized by the death of brain cells, eventually leading to memory loss, cognitive dysfunction and dementia. Accounting for 60-70% of cases of dementia, Alzheimer's disease is known to be the sixth leading cause of death in the US. Presently, around seven million Americans of all ages are living with Alzheimer's and this number is projected to reach around 13 million by 2050. The primary symptoms associated with Alzheimer's disease include disorientation, personality / behavioral changes, confusion about events / time / place and severe memory loss. In addition, people suffering from this disease are known to face difficulty in speaking, swallowing and walking. Notably, as the disease progresses, the aforementioned symptoms become more pronounced and contribute to the death of brain cells. Consequently, the advancements in innovative Alzheimer's therapies offer lucrative opportunities to stakeholders engaged in this field.

Given the socioeconomic burden associated with Alzheimer's, pharmaceutical players have been looking for reliable diagnostic tests and effective Alzheimer's treatment alternatives that can slow the progression of this disease. Presently, over 160 companies, based in different regions of the world, have taken initiatives to develop drug therapies for Alzheimer's treatment.

ALZHEIMER'S DISEASE MARKET: KEY INSIGHTS

The report delves into the current state of the Alzheimer's disease market and identifies potential growth opportunities within the industry. Some key findings from the report include:

Presently, over 160 companies, based in different regions of the world, have taken initiatives to develop drug therapies for Alzheimer's disease; the market is characterized by a mix of well-established and small firms.
The pipeline features 240+ drug therapies being evaluated either as monotherapies or in combination with other interventions across different stages of development; most of these are designed for oral administration.

There has been a notable increase in published scientific literature related to the diagnosis, treatment and management of Alzheimer's disease.
The intellectual property associated with Alzheimer's disease has also increased, as numerous patents related to the drug molecules have been filed by / granted to various organizations.
In the past few years, several organizations have extended financial support to aid the ongoing research and development activities in this domain.
In the past decade, several clinical trials have been registered for evaluating drug therapies for Alzheimer's disease, across different geographical regions; a number of these trials have already been completed.
Several investors have invested over USD 4 billion across 164 instances in the recent past, owing to the benefits and opportunities associated with drug candidates being developed to treat this clinical condition.
The overall market opportunity for Alzheimer's disease therapies is likely to be distributed across different types of treatments, symptomatic indications and key geographical regions

ALZHEIMER'S DISEASE MARKET: KEY SEGMENTS

Disease Modifying Segment Occupy the Largest Share of the Global Alzheimer's Disease Market

Based on the type of treatment, the market is segmented into symptomatic and disease modifying types of treatments. At present, the disease modifying segment holds the maximum share of the global Alzheimer's disease market. Further, the symptomatic segment is likely to grow at a faster pace compared to the other segments.

By Symptomatic Indications, Insomnia is the Fastest Growing Segment of the Global Alzheimer's Disease Market During the Forecast Period

Based on the symptomatic indications, the market is segmented into dementia, insomnia, and other psychological symptoms. Currently, the dementia segment captures the highest proportion of the global Alzheimer's disease market owing to the growing number of therapeutic drugs being developed to treat cognitive symptoms. Further, it is worth highlighting that the Alzheimer's disease market for insomnia is likely to grow at a relatively higher CAGR.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, and Asia-Pacific and Rest of the World. Currently, North America dominates the Alzheimer's disease market and accounts for the largest revenue share due to the favorable regulatory environment in this region. In fact, regulatory bodies in North America have recently approved several new Alzheimer's drugs, providing patients with access to innovative therapies and boosting market growth. Additionally, the market in Europe is likely to grow at a higher CAGR in the coming years.

Example Players in the Alzheimer's Disease Market

AbbVie
AC Immune
Biogen
Eisai
Eli Lilly and Company
GlaxoSmithKline
Grifols
Janssen Pharmaceutical
Neurim Pharmaceuticals
Novartis
Novo Nordisk
Roche
Takeda Pharmaceutical

ALZHEIMER'S DISEASE MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global Alzheimer's disease market, focusing on key market segments, including [A] type of treatment, [B] symptomatic indications, and [C] key geographical regions.
Market Landscape: A comprehensive evaluation of the drugs developed for the treatment of Alzheimer's, based on several relevant parameters, such as [A] current status of development, [B] phase of development of lead candidates, [C] type of biologic, [D] target disease stage, [E] type of treatment, [F] mechanism of action, [G] route of administration, [H] dosing frequency, [I] type of therapy and [J] path to clinic. Additionally, a comprehensive evaluation of the drug developer(s) involved in the domain, based on several relevant parameters, such as [K] year of establishment, [L] company size and [M] geographical location of headquarters.
Company Profiles: In-depth profiles of key players engaged in the development of therapeutics for Alzheimer's disease, focusing on [A] overview of the company, [B] financial information (if available), [C] product portfolio, and [D] recent developments and an informed future outlook.
Case Study: A detailed discussion on over 110 discontinued drugs and terminated trials, based on various parameters, such as [A] year of discontinuation, [B] reason(s) for discontinuation, [C] phase of discontinuation, [D] mechanism of action of the terminated drugs, [E] type of indication, [F] reason for termination, [G] affiliated stakeholders. Additionally, a detailed assessment of 180 terminated clinical trials, based on various parameters, such as [H] year of termination and [I] key geographies across which these trials were being conducted.
Publication Analysis: An insightful analysis of around 20,000 peer-reviewed scientific articles related to research on Alzheimer's disease, based on various relevant parameters, such as [A] year of publication, [B] key focus area, [C] type of molecule, [D] popular keywords, and [E] key journals.
Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the Alzheimer's disease market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] focus area, [D] type of molecule, [E] most active players (in terms of the number of partnerships signed) and [F] geographical distribution of partnership activity.
Funding and Investments: An in-depth analysis of the fundings raised by companies engaged in Alzheimer's disease market, based on relevant parameters, such as [A] year of funding, [B] amount invested, [C] type of funding, [D] geographical analysis, [E] most active players and [F] most active investors.
Grants Analysis: A comprehensive assessment of grants that have been awarded to research institutes in the Alzheimer's disease domain, based on various relevant parameters, such as [A] year of grant award, [B] grant amount awarded, [C] administering institute center, [D] support period, [E] type of grant application, [F] grant activity code, [G] emerging focus area, [H] purpose of grant award, [I] type of recent organization, [J] popular NIH department and [K] prominent program officers.
Clinical Trial Analysis: An insightful analysis of clinical trials related to therapies being developed for the treatment of Alzheimer's, based on several parameters, such as [A] current trial status, [B] trial registration year, [C] phase of development, [D] study design, [E] leading industry sponsors, [F] study focus, [G] target indication(s), [H] focus areas, [I] target therapeutic area(s), [J] enrolled patient population and [K] regional distribution of trials.
Patent Analysis: An in-depth analysis of patents filed / granted till date in the Alzheimer's disease domain, based on various relevant parameters, such as [A] publication year, [B] geography, [C] CPC symbols, [D] emerging focus areas, [E] type of applicant, [F] leading industry players and [G] patent valuation analysis.
Non-Pharmacological Interventions and Diagnostics: A detailed discussion on the various non-pharmacological interventions, including [A] cognition / emotion-oriented therapies, [B] sensory simulation therapies and [C] other psychological interventions. Additionally, a discussion of the companies that offer such solutions, providing information on the [D] devices / products and [E] mechanisms of action / working principles.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. An Overview of Alzheimer's Disease
- 3.1.1. Alzheimer's Disease: Signs and Symptoms
- 3.1.2. Causes of Alzheimer's Disease
- 3.1.3. Stages of Alzheimer's Disease
3.2. Alzheimer's Disease Management: Programs Undertaken by The National Institutes of Health
3.3. Alzheimer's Disease Management
3.4. Digital Biomarkers in Alzheimer's Disease
- 3.4.1. Potential of Digital Biomarkers in Alzheimer's Disease
- 3.4.2. Sensors or Digital Senses in Wearable / Mobile Devices for Alzheimer's Disease

4. PIPELINE REVIEW: MARKETED AND CLINICAL- STAGE DRUGS

4.1. Analysis Methodology and Key Parameters
4.2. Alzheimer's Disease Therapies: Marketed and Development Pipeline
- 4.2.1. Analysis by Phase of Development
- 4.2.2. Analysis by Type of Molecule
- 4.2.3. Analysis by Target Disease Stage
- 4.2.4. Analysis by Type of Treatment
- 4.2.5. Analysis by Mechanism of Action
- 4.2.6. Analysis by Route of Administration
- 4.2.7. Analysis by Dosing Frequency
- 4.2.8. Analysis by Type of Therapy
- 4.2.9. Analysis by Path to Clinic
- 4.2.10. Grid Analysis: Distribution by Phase of Development, Path to Clinic and Type of Therapy
4.4. Alzheimer's Disease Therapies: List of Developers
- 4.4.1. Analysis by Year of Establishment
- 4.4.2. Analysis by Company Size and Geographical Location of Headquarters
- 4.4.3. Leading Players: Analysis by Number of Therapies
- 4.4.4. Analysis by Geography

5. COMPANY PROFILES

5.1. AbbVie
- 5.1.1. Company Overview
- 5.1.2. Financial Information
- 5.1.3. Product Portfolio
- 5.1.4. Recent Developments and Future Outlook
5.2. AC Immune
- 5.2.1. Company Overview
- 5.2.2. Financial Information
- 5.2.3. Product Portfolio
- 5.2.4. Recent Developments and Future Outlook
5.3. Biogen
- 5.3.1. Company Overview
- 5.3.2. Financial Information
- 5.3.3. Product Portfolio
- 5.3.4. Recent Developments and Future Outlook
5.4. Eisai
- 5.4.1. Company Overview
- 5.4.2. Financial Information
- 5.4.3. Product Portfolio
- 5.4.4. Recent Developments and Future Outlook
5.5. Eli Lilly and Company
- 5.5.1. Company Overview
- 5.5.2. Financial Information
- 5.5.3. Product Portfolio
- 5.5.4. Recent Developments and Future Outlook
5.6. GlaxoSmithKline
- 5.6.1. Company Overview
- 5.6.2. Financial Information
- 5.6.3. Product Portfolio
- 5.6.4. Recent Developments and Future Outlook
5.7. Grifols
- 5.7.1. Company Overview
- 5.7.2. Financial Information
- 5.7.3. Product Portfolio
- 5.7.4. Recent Developments and Future Outlook
5.8. Janssen Pharmaceutical
- 5.8.1. Company Overview
- 5.8.2. Financial Information
- 5.8.3. Product Portfolio
- 5.8.4. Recent Developments and Future Outlook
5.9. Neurim Pharmaceuticals
- 5.9.1. Company Overview
- 5.9.2. Financial Information
- 5.9.3. Product Portfolio
- 5.9.4. Recent Developments and Future Outlook
5.10. Novartis
- 5.10.1. Company Overview
- 5.10.2. Financial Information
- 5.10.3. Product Portfolio
- 5.10.4. Recent Developments and Future Outlook
5.11. Novo Nordisk
- 5.11.1. Company Overview
- 5.11.2. Financial Information
- 5.11.3. Product Portfolio
- 5.11.4. Recent Developments and Future Outlook
5.12. Roche
- 5.12.1. Company Overview
- 5.12.2. Financial Information
- 5.12.3. Product Portfolio
- 5.12.4. Recent Developments and Future Outlook
5.13. Takeda Pharmaceutical
- 5.13.1. Company Overview
- 5.13.2. Financial Information
- 5.13.3. Product Portfolio
- 5.13.4. Recent Developments and Future Outlook

6. CASE STUDY: TERMINATED DRUGS

6.1. Chapter Overview
6.2. Alzheimer's Disease Therapies: List of Terminated Drugs
- 6.2.1. Analysis by Year of Discontinuation
- 6.2.2. Analysis by Phase of Discontinuation
- 6.2.3. Analysis by Mechanism of Action
- 6.2.4. Analysis by Type of Indication
- 6.2.5. Analysis by Reason for Termination
- 6.2.6. Analysis by Affiliated Stakeholders
6.3. Alzheimer's Disease Therapies: List of Terminated Clinical Trials
- 6.3.1. Distribution by Study Start Year and Year of Termination of Clinical Trials
- 6.3.2. Analysis by Location of Trials
6.4. Concluding Remarks

7. PUBLICATION ANALYSIS

7.1. Analysis Methodology and Key Parameters
7.2. Alzheimer's Disease: List of Publications
7.3. Analysis by Year of Publication
7.4. Analysis by Key Focus Area
7.5. Word Cloud of Study Titles
7.6. Top Journal: Analysis by Number of Publications
7.6. Top Author: Analysis by Number of Publications

8. PARTNERSHIPS AND COLLABORATIONS

8.1. Analysis Methodology and Key Parameters
8.2. Partnership Models
8.3. Alzheimer's Disease: List of Partnerships and Collaborations
- 8.3.1. Analysis by Year of Partnership
- 8.3.2. Analysis by Type of Partnership
- 8.3.3. Analysis by Type of Partnership and Focus Area of Partnership
- 8.3.4. Analysis by Type of Partnership and Type of Molecule
- 8.3.5. Most Active Players: Analysis by Number of Partnerships
- 8.3.6. Regional Analysis
- 8.3.7. Intercontinental and Intracontinental Agreements

9. FUNDING AND INVESTMENT ANALYSIS

9.1. Analysis Methodology and Key Parameters
9.2. Types of Funding
9.3. Funding and Investment Analysis
- 9.3.1. Analysis by Year of Investment
- 9.3.2. Analysis by Amount Invested
- 9.3.3. Analysis by Type of Funding
- 9.3.4 Analysis by Amount Invested Across Different Types of Molecules
- 9.3.5 Analysis by Amount Invested Across Different Types of Mechanism of Action
- 9.3.6. Regional Analysis by Amount Invested
- 9.3.7. Most Active Players: Analysis by Number of Funding Instances
- 9.3.8. Most Active Investors: Analysis by Amount Funded

10. GRANT ANALYSIS

10.1. Analysis Methodology and Key Parameters
10.2. Alzheimer's Disease: List of Academic Grants
- 10.2.1. Analysis by Year of Grant Award
- 10.2.2. Analysis by Grant Amount Awarded
- 10.2.3. Analysis by Administering Institute Center
- 10.2.4. Analysis by Support Period
- 10.2.5. Analysis by Administering Institute Center and Support Year
- 10.2.6. Analysis by Type of Grant Application
- 10.2.7. Analysis by Grant Activity Code
- 10.2.8. Word Cloud of Study Titles
- 10.2.9. Analysis by Purpose of Grant Award
- 10.2.10. Analysis by Type of Recipient Organization
- 10.2.11. Popular NIH Departments: Analysis by Number of Grants
- 10.2.12. Prominent Program Officers: Analysis by Number of Grants

11. CLINICAL TRIAL ANALYSIS

11.1. Analysis Methodology and Key Parameters
11.2. Alzheimer's Disease: Clinical Trial Analysis
- 11.3.1. Analysis by Trial Status
- 11.3.2. Analysis by Trial Registration Year
- 11.3.3. Analysis by Type of Sponsor / Collaborator
- 11.3.3. Analysis by Type of Study Design
- 11.3.4. Analysis by Registration Year and Type of Study
- 11.3.5. Analysis by Patient Enrollment
- 11.3.6. Year-wise Trend of Completed and Recruiting Trials
- 11.3.7. Analysis by Age Category
- 11.3.8. Word Cloud of Study Titles
- 11.3.9. Most Active Industry Players: Analysis by Number of Registered Trials
- 11.3.10. Most Active Non- Industry Players: Analysis by Number of Registered Trials
- 11.3.11. Analysis by Trial Location
- 11.3.12. Analysis by Trial Status and Geography

12. PATENT ANALYSIS

12.1. Analysis Methodology and Key Parameters
12.2. Alzheimer's Disease: Patent Analysis
- 12.2.1. Analysis by Patent Application Year
- 12.2.2. Analysis by Geography
- 12.2.3. Analysis by CPC Symbols
- 12.2.4. Word Cloud: Emerging Focus Areas
- 12.2.5. Analysis by Type of Applicant
- 12.2.6. Leading Players: Analysis by Number of Patents
- 12.2.7 Leading Players: Analysis by Number of International Patents
- 12.2.8. Patent Valuation Analysis

13. NON-PHARMACOLOGICAL INTERVENTIONS AND DIAGNOSTICS

13.1. Non-Pharmacological Interventions for Alzheimer's Disease
- 13.1.1. Cognition / Emotion-Oriented Interventions
  - 13.1.1.1. Reminiscence Therapy
  - 13.1.1.2. Simulated Presence Therapy
- 13.1.2. Sensory Stimulation-based Interventions
  - 13.1.2.1. Virtual Reality
  - 13.1.2.2. Music Therapy
  - 13.1.2.3. Light Therapy
  - 13.1.2.4. Aromatherapy
  - 13.1.2.5. Reflexology
- 13.1.3. Other Psycho-social Interventions
  - 13.1.3.1. Animal-Assisted Therapy

14. MARKET SIZING AND OPPORTUNITY ANALYSIS

14.1. Forecast Methodology and Key Assumptions
14.2. Global Alzheimer's Disease Market, Till 2035
14.3. Global Alzheimer's Disease Market, Till 2035: Distribution by Type of Treatment
14.4. Global Alzheimer's Disease Market, Till 2035: Distribution by Type of Target Disease Indication
14.5. Global Alzheimer's Disease Market, Till 2035: Distribution by Geography
- 14.5.1. Alzheimer's Disease Market in North America, Till 2035
  - 14.5.1.1. Alzheimer's Disease Market in North America, Till 2035: Distribution by Type of Treatment
    - 14.5.1.1.1. Alzheimer's Disease Market in North America, Till 2035: Distribution by Symptomatic Treatment
      - 14.5.1.1.1.1. Alzheimer's Disease Market in North America, Till 2035: Share of Dementia in Symptomatic Treatment Market
      - 14.5.1.1.1.2. Alzheimer's Disease Market in North America, Till 2035: Share of Insomnia in Symptomatic Treatment Market
      - 14.5.1.1.1.3. Alzheimer's Disease Market in North America, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market
    - 14.5.1.1.2. Alzheimer's Disease Market in North America, Till 2035: Distribution by Disease Modifying Treatment
- 14.5.2. Alzheimer's Disease Market in Europe, Till 2035
  - 14.5.2.1. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Type of Treatment
    - 14.5.2.1.1. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Symptomatic Treatment
      - 14.5.2.1.1.1. Alzheimer's Disease Market in Europe, Till 2035: Share of Dementia in Symptomatic Treatment Market
      - 14.5.2.1.1.2. Alzheimer's Disease Market in Europe, Till 2035: Share of Insomnia in Symptomatic Treatment Market
      - 14.5.2.1.1.3. Alzheimer's Disease Market in Europe, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market
    - 14.5.2.1.2. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Disease Modifying Treatment
- 14.5.3. Alzheimer's Disease Market in Asia-Pacific, Till 2035
  - 14.5.3.1. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Type of Treatment
    - 14.5.3.1.1. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Symptomatic Treatment
      - 14.5.3.1.1.1. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Dementia in Symptomatic Treatment Market
      - 14.5.3.1.1.2. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Insomnia in Symptomatic Treatment Market
      - 14.5.3.1.1.3. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market
    - 14.5.3.1.2. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Disease Modifying Treatment

15. CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS

16.1. Cognition Therapeutics
- 16.1.1. Company Snapshot
- 16.1.1. Interview Transcript: Kenneth Moch (President and Chief Executive Officer)
16.2. ArmaGen
- 16.2.1. Company Snapshot
- 16.2.2. Interview Transcript: Mathias Schmidt (Chief Executive Officer)
16.2. ICB International
- 16.2.1. Company Snapshot
- 16.3.2. Interview Transcript: Ram Bhatt (Chief Executive Officer, Chairman and Founder)

アルツハイマー病市場：治療タイプ別、対症的適応別、主要地域別

Alzheimer's Disease Market Distribution by Type of Treatment, Symptomatic Indications, and Key Geographical Regions

アルツハイマー病市場：成長と動向

アルツハイマー病市場：主要インサイト

アルツハイマー病市場：主要セグメント

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 パイプラインレビュー：市販済みおよび臨床段階の医薬品

第5章 企業プロファイル

第6章 ケーススタディ：廃止された薬剤

第7章 出版物の分析

第8章 パートナーシップとコラボレーション

第9章 資金調達と投資分析

第10章 助成金分析

第11章 臨床試験の分析

第12章 特許分析

第13章 非薬理学的介入と診断

第14章 市場規模の評価と機会分析

第15章 結論

第16章 エグゼクティブ洞察

第17章 付録1：表形式データ

第18章 付録2：企業・団体一覧

List of Tables

List of Figures

ALZHEIMER'S DISEASE MARKET: OVERVIEW

ALZHEIMER'S DISEASE MARKET: GROWTH AND TRENDS

ALZHEIMER'S DISEASE MARKET: KEY INSIGHTS

ALZHEIMER'S DISEASE MARKET: KEY SEGMENTS

Example Players in the Alzheimer's Disease Market

ALZHEIMER'S DISEASE MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. PIPELINE REVIEW: MARKETED AND CLINICAL- STAGE DRUGS

5. COMPANY PROFILES

6. CASE STUDY: TERMINATED DRUGS

7. PUBLICATION ANALYSIS

8. PARTNERSHIPS AND COLLABORATIONS

9. FUNDING AND INVESTMENT ANALYSIS

10. GRANT ANALYSIS

11. CLINICAL TRIAL ANALYSIS

12. PATENT ANALYSIS

13. NON-PHARMACOLOGICAL INTERVENTIONS AND DIAGNOSTICS

14. MARKET SIZING AND OPPORTUNITY ANALYSIS

15. CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

第1章序文

第2章エグゼクティブサマリー

第3章イントロダクション

第4章パイプラインレビュー：市販済みおよび臨床段階の医薬品

第5章企業プロファイル

第6章ケーススタディ：廃止された薬剤

第7章出版物の分析

第8章パートナーシップとコラボレーション

第9章資金調達と投資分析

第10章助成金分析

第11章臨床試験の分析

第12章特許分析

第13章非薬理学的介入と診断

第14章市場規模の評価と機会分析

第15章結論

第16章エグゼクティブ洞察

第17章付録1：表形式データ

第18章付録2：企業・団体一覧